Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 03 May 2023
Patients' "show rates" improved, especially for those who were, when artificial intelligence (AI) was used to predict the likelihood of missed appointments in a busy clinic and was then followed by personal outreach to at-risk patients.
Read Full NewsThe recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.
The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.
1.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
2.
New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.
3.
Research finds stark disparities in treatment and survival time for people with pancreatic cancer
4.
Tumor characteristics found to differ for melanomas in children, teens and young adults
5.
Relationship-building key to addressing oncologist shortages in rural care
1.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
2.
Colon cancer: Risk factors, warning signs and treatment options
3.
Exploring the Latest Advances in Hodgkin's Lymphoma Treatment
4.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
5.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge